Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34+ selected stem cell boost
- Development stage
- Unknown
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34+ selected stem cell boost (CD34+-SCB) is a cellular therapy procedure involving the enrichment and infusion of CD34+ hematopoietic stem and progenitor cells (HSPCs) from a donor's mobilized peripheral blood into a recipient, typically without prior conditioning. This intervention is primarily used to treat complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT), such as poor graft function (PGF), prolonged isolated thrombocytopenia, or mixed chimerism. By providing a concentrated dose of progenitor cells while depleting T-cells (via CD34+ selection, often using systems like CliniMACS), the boost aims to restore hematopoiesis and improve donor chimerism with a reduced risk of inducing or exacerbating graft-versus-host disease (GVHD). It is also being explored for persistent cytopenias following CAR T-cell therapy.
- Other names
- CD34+ stem cell boostCD34-selected stem cell boostCD-34-selected stem cell boostCD 34-selected stem cell boostCD34+ selected SCB
Beyond the preview
Go deeper on CD34+ selected stem cell boost.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34+ selected stem cell boost.